AI/ML Innovations Closes Acquisition of Quantum Sciences Ltd.
AI/ML Innovations (AIMLF) has completed the acquisition of Quantum Sciences , a company specializing in AI-driven digital healthcare solutions. The acquisition, valued at $750,000, was executed through the issuance of 10 million company shares at $0.075 per share.
Quantum's focus includes developing technologies for cardiovascular disease, neurodegenerative disorders, and metabolic conditions. The company has spent two years designing software to improve patient health management through a centralized information system.
The acquisition brings together AI/ML's signal processing capabilities with Quantum's experienced medical team, including notable cardiologists Dr. Alan Rabinowitz, Dr. Marc W. Deyell, and Dr. Brett Heilbron from St. Paul's Hospital. The shares issued are subject to trading restrictions and voluntary escrow conditions.
AI/ML Innovations (AIMLF) ha completato l'acquisizione di Quantum Sciences, un'azienda specializzata in soluzioni sanitarie digitali guidate dall'IA. L'acquisizione, del valore di 750.000 dollari, è stata effettuata tramite l'emissione di 10 milioni di azioni della società a 0,075 dollari per azione.
Il focus di Quantum include lo sviluppo di tecnologie per le malattie cardiovascolari, i disturbi neurodegenerativi e le condizioni metaboliche. L'azienda ha dedicato due anni alla progettazione di software per migliorare la gestione della salute dei pazienti attraverso un sistema informativo centralizzato.
L'acquisizione unisce le capacità di elaborazione dei segnali di AI/ML con l'esperto team medico di Quantum, che include rinomati cardiologi come il Dr. Alan Rabinowitz, il Dr. Marc W. Deyell e il Dr. Brett Heilbron dell'ospedale di St. Paul. Le azioni emesse sono soggette a restrizioni di trading e condizioni di escrow volontarie.
AI/ML Innovations (AIMLF) ha completado la adquisición de Quantum Sciences, una empresa especializada en soluciones de atención médica digital impulsadas por IA. La adquisición, valorada en 750,000 dólares, se llevó a cabo mediante la emisión de 10 millones de acciones de la empresa a 0.075 dólares por acción.
El enfoque de Quantum incluye el desarrollo de tecnologías para enfermedades cardiovasculares, trastornos neurodegenerativos y condiciones metabólicas. La empresa ha dedicado dos años a diseñar software para mejorar la gestión de la salud de los pacientes a través de un sistema de información centralizado.
La adquisición une las capacidades de procesamiento de señales de AI/ML con el experimentado equipo médico de Quantum, que incluye a destacados cardiólogos como el Dr. Alan Rabinowitz, el Dr. Marc W. Deyell y el Dr. Brett Heilbron del Hospital de San Pablo. Las acciones emitidas están sujetas a restricciones de negociación y condiciones de depósito voluntarias.
AI/ML Innovations (AIMLF)는 AI 기반 디지털 건강 관리 솔루션을 전문으로 하는 Quantum Sciences의 인수를 완료했습니다. 이 인수는 750,000 달러의 가치로, 주당 0.075 달러에 1천만 주의 회사 주식을 발행하여 이루어졌습니다.
Quantum의 주요 초점은 심혈관 질환, 신경퇴행성 장애 및 대사 상태를 위한 기술 개발입니다. 이 회사는 중앙 집중식 정보 시스템을 통해 환자 건강 관리를 개선하기 위한 소프트웨어를 설계하는 데 2년을 투자했습니다.
이번 인수로 AI/ML의 신호 처리 능력과 Quantum의 경험이 풍부한 의료진, 즉 St. Paul 병원의 저명한 심장 전문의 Alan Rabinowitz 박사, Marc W. Deyell 박사, Brett Heilbron 박사와 함께하게 됩니다. 발행된 주식은 거래 제한 및 자발적인 에스크로 조건의 적용을 받습니다.
AI/ML Innovations (AIMLF) a finalisé l'acquisition de Quantum Sciences, une entreprise spécialisée dans les solutions de santé numérique basées sur l'IA. L'acquisition, d'une valeur de 750 000 dollars, a été réalisée par l'émission de 10 millions d'actions de la société au prix de 0,075 dollar par action.
Le domaine d'intervention de Quantum comprend le développement de technologies pour les maladies cardiovasculaires, les troubles neurodégénératifs et les conditions métaboliques. L'entreprise a passé deux ans à concevoir un logiciel pour améliorer la gestion de la santé des patients à travers un système d'information centralisé.
Cette acquisition réunit les capacités de traitement des signaux d'AI/ML avec l'équipe médicale expérimentée de Quantum, qui comprend des cardiologues renommés tels que le Dr Alan Rabinowitz, le Dr Marc W. Deyell et le Dr Brett Heilbron de l'hôpital de St. Paul. Les actions émises sont soumises à des restrictions de négociation et à des conditions d'entiercement volontaires.
AI/ML Innovations (AIMLF) hat die Übernahme von Quantum Sciences abgeschlossen, einem Unternehmen, das sich auf KI-gesteuerte digitale Gesundheitslösungen spezialisiert hat. Die Übernahme, die mit 750.000 Dollar bewertet wurde, erfolgte durch die Ausgabe von 10 Millionen Unternehmensaktien zu je 0,075 Dollar.
Der Fokus von Quantum liegt auf der Entwicklung von Technologien für Herz-Kreislauf-Erkrankungen, neurodegenerative Erkrankungen und Stoffwechselerkrankungen. Das Unternehmen hat zwei Jahre damit verbracht, Software zu entwickeln, um das Gesundheitsmanagement der Patienten durch ein zentrales Informationssystem zu verbessern.
Die Übernahme vereint die Signalverarbeitungsfähigkeiten von AI/ML mit dem erfahrenen medizinischen Team von Quantum, das namhafte Kardiologen wie Dr. Alan Rabinowitz, Dr. Marc W. Deyell und Dr. Brett Heilbron vom St. Paul’s Hospital umfasst. Die ausgegebenen Aktien unterliegen Handelsbeschränkungen und freiwilligen Treuhandbedingungen.
- Strategic acquisition valued at $750,000
- Addition of experienced medical team including three prominent cardiologists
- Integration of complementary technologies in AI healthcare solutions
- Expansion into cardiovascular, neurodegenerative, and metabolic healthcare markets
- Share dilution through issuance of 10 million new shares
- Trading restrictions on newly issued shares until April 2025
Strategic Expansion into Cardio AI-Driven Healthcare Solutions
Collaboration to Enhance Patient-Centered Digital Healthcare Technologies
Welcomes Key Industry Experts to Drive Innovation
VICTORIA, BC / ACCESSWIRE / December 24, 2024 / AI/ML Innovations Inc. (the "Company" or "AI/ML") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce that it has closed the arms-length share purchase previously announced on December 10, 2024 ("Acquisition") and acquired all of the issued and outstanding shares of Quantum Sciences Ltd. ("Quantum").
Quantum specializes in developing innovative digital healthcare solutions powered by artificial intelligence ("AI"), machine learning, and quantum-inspired methodologies. The company focuses on technologies addressing critical healthcare challenges, including cardiovascular disease, neurodegenerative disorders, and metabolic conditions. The Acquisition provides synergies and opportunities to leverage Quantum's experienced medical team and AI/ML's unique signal processing capabilities to explore and evaluate various cardio-focused applications.
The principals of Quantum have spent the last 2 years designing a software product that will enable patients to have more control over their health trajectory by addressing and removing current impediments and inefficiencies in the existing medical domain that come from a absence of a centralized patient information system.
According to Mark Orsmond, Quantum's CEO "On almost a weekly basis we are hearing and seeing how AI is transforming and redefining the medical landscape. To date, our team has been highly impressed with AI/ML's proprietary technology and its potential applications. In my view, this Acquisition brings together all the key pieces necessary for a highly productive commercialization environment including valuable access to a unique technology, experienced and skilled human resources, real-time/real-world data and invaluable physician led input. We are delighted to be working with Paul Duffy and his team as we move forward together".
Quantum team members that will be working with AI/ML include:
Dr. Alan Rabinowitz, Quantum's Clinical Strategist and Advisor, was formerly Director of the Coronary Care Unit at St Paul's Hospital and is currently a cardiologist and Clinical Associate Professor in the Division of Cardiology at St Paul's Hospital. Alan has held numerous advisory roles to both public and private healthcare entities globally and has also been at the forefront of various entrepreneurial initiatives with a specific focus on disruptive innovation and data innovation in healthcare and the life sciences. Alan received his medical degree from the University of Cape Town, South Africa, completed his internal medicine and cardiology training at the University of Toronto and undertook subsequent training in interventional cardiology at St. Paul's Hospital, University of British Columbia ("UBC") in Vancouver, Canada.
Dr. Marc W. Deyell, Quantum's Product Development Advisor - Research & Innovation, is the Director of the Heart Rhythm Program at St. Paul's Hospital in Vancouver, Canada having joined the Heart Rhythm team at St. Paul's and Vancouver General Hospitals of the UBC Division of Cardiology in 2012. He is also an Associate Professor of Medicine at UBC and an active researcher. His clinical and research interests center around the epidemiology, health outcomes and ablation of arrhythmias, with a focus in ambulatory heart rhythm monitoring and ventricular arrhythmias. He received his medical degree from the University of Alberta. He completed a Masters of Epidemiology at the University of Calgary and his cardiology and electrophysiology training at the University of British Columbia, and undertook an advanced fellowship in Electrophysiology, focused on complex ablation, at the University of Pennsylvania.
Dr. Brett Heilbron, Quantum's Product Development Advisor, has been based at St. Paul's Hospital since 1997, where he has a clinical practice and works in the Cardiac Catheterization Laboratory. He is the Medical Director of the Electrodiagnostics program at St. Paul's, and Mount St. Joseph's Hospitals, and a Clinical Associate Professor at the University of British Columbia. He is also the Cardiology Consultant for Lifelabs British Columbia. Brett completed his undergraduate degree at the University of Cape Town (South Africa), and then practiced as a rural family physician in Newfoundland and Manitoba for 4 years. He completed Internal Medicine and Cardiology training at UBC in 1995. He has Level 3 Certification in Cardiac Computed Tomography and is a Diplomate of the Certification Board in Cardiac Computed Tomography and a Fellow of the Society of Cardiovascular Computed Tomography.
Paul Duffy, Chief Executive Officer of the AI/ML, comments: "The close of the Acquisition of Quantum provides an exciting next step for the Company as we advance our objective of becoming a leader in delivering personalized medicine solutions. I am furthermore very happy to be working with Mark Orsmond, Quantum's founder, who has a proven track record and achieved considerable success in developing three separate health care businesses that were sold to Well Health Technologies Corp. (TSX:WELL). We welcome his business experience and the deep innovation and knowledge of the Quantum medical advisory team as we move forward together to advance proactive, data-driven technologies and solutions that we expect will create improved health outcomes for patients and more efficient workflows."
The Company satisfied the Acquisition purchase price of
The Company notes that neither it nor Quantum Science are involved in the development or exploitation of quantum technology or quantum computers.
On behalf of the Board of Directors
Tim Daniels, Chairman
About AI/ML Innovations Inc. https://aiml-innovations.com/
AI/ML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence: (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through strategic partnerships with Health Gauge Inc. (
For more information about AI/ML Innovations:
For detailed information please see AI/ML's website or the Company's filed documents at www.sedarplus.ca
For further information, contact: Blake Fallis at (778) 405-0882 or info@aiml-innovations.com
The Canadian Securities Exchange has in no way passed upon the merits of the Company and has neither approved nor disapproved the contents of this press release. Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release contains "forward-looking statements" within the meaning of the securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. In addition, we cannot assure that any patent will be issued as a result of a pending patent application or, if issued, whether it will be issued in a form that will be advantageous to us. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time at sedarplus.ca. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. The Company is not responsible for the contents of third-party websites.
SOURCE: AI/ML Innovations, Inc.
View the original press release on accesswire.com
FAQ
What is the value of AI/ML Innovations' acquisition of Quantum Sciences?
What are the trading restrictions on AIMLF shares issued for the Quantum acquisition?
What healthcare areas will AIMLF expand into through the Quantum Sciences acquisition?
How will the Quantum Sciences acquisition benefit AIMLF's technology capabilities?
What is the escrow release schedule for AIMLF shares issued in the Quantum acquisition?
